^
Association details:
| Biomarker: | TP53 mutation |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | atorvastatin (HMG-CoA reductase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Statins inhibit proliferation and induce apoptosis in triple-negative breast cancer cells
Published date:
07/14/2022
Excerpt:
The anti-proliferative effects of 2 widely used statins were investigated on a panel of 15 cell lines representing the different molecular subtypes of breast cancer....cell lines containing mutant p53 were more responsive to both statins than cell lines expressing wild-type p53….Finally, we found synergistic growth inhibition between simvastatin and the IGF-1R inhibitor, OSI-906 as well as between simvastatin and doxorubicin or docetaxel....Based on our findings, we suggest that these trials investigate statins in combination with either doxorubicin or docetaxel and include p53 mutational status as a potential predictive biomarker.
DOI:
10.1007/s12032-022-01733-9
